Recent insider trends for CRISPR Therapeutics AG (NASDAQ:CRSP) have caught the attention of investors. Insider activity is often a strong indicator of future performance in a stock, and if the data on CRSP is anything to go by, investors should pay attention.
Institutions own 24.53% of CRISPR Therapeutics AG (CRSP)’s shares. The total value of these holdings, in millions, is $393. Among active positions in the latest quarter, 47 holders increased their positions by a total of 2.24 million shares, 19 holders decreased the positions by a total of 1.41 million shares, and 16 holders held their positions. This works out to a net increase in ownership of 827729 shares, and suggests that institutions are feeling bullish about the stock.
Among new and sold out positions, 32 holders initiated new positions by a total of 1.38 million shares and 11 holders exited their positions by a total of 160315 shares. This nets out to an increase of 1.22 million shares and is a bullish sign for CRSP.
In the last three months, insiders executed a total of 29 trades. 3 of these were buys and 26 were sells. Insider ownership decreased by a total of 488185 shares, which suggests that CRSP’s key executives are feeling less optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 8 buys and 109 sells, and ownership decreased by a net of 8.64 million shares.
Short interest, or the number of a stock’s tradable shares currently being shorted, is another metric investors use to get a pulse on sentiment. CRISPR Therapeutics AG (NASDAQ:CRSP)’s short interest is 1.25 million shares, or 6.65% of the float. This represents a decrease of -12% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Insider data can help an investor form an outlook on a stock, but it’s important to supplement this data with other information such as technical indicators to form a more complete view. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that CRSP is a buy, which implies that CRSP is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bearish. Technical indicators (also) suggest that CRISPR Therapeutics AG (NASDAQ:CRSP) is undervalued.